A Safety and Efficacy Study of Eltrombopag in Subjects With AML

NCT01890746 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

148

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Leukaemia

Interventions

DRUG: Daunorubicin
DRUG: Cytarabine
DRUG: Eltrombopag
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals